title: Re: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efﬁcacy in melanoma.
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, USA.
authors.forename: D
authors.initials: D
authors.lastname: Diwakar
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, USA.
authors.forename: T
authors.initials: T
authors.lastname: Choi
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, USA.
authors.forename: T H
authors.initials: TH
authors.lastname: Tawbi
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, USA kirkwoodjm@upmc.edu.
authors.forename: J M
authors.initials: JM
authors.lastname: Kirkwood
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use*; D016131:Lymphocyte Subsets / Q000187:drug effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D010091:Oximes / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D007211:Indoles; D010091:Oximes; D013449:Sulfonamides